FDA Assessing Zolgensma Data Accuracy Issues Tops SPT Week in Review

5. FDA Approves First Therapy for Rare, Debilitating Tumor

Pexidartinib (Turalio, Daiichi Sankyo) is indicated for adult patients with symptomatic tenosynovial giant cell tumor associated with severe morbidity or functional limitations and not amenable to improvement with surgery. Read more.

4. Cancer Cell Growth Mechanism Discovered

Research could lead to the development of new cancer treatments to stop tumor growth. Read more.

3. The Journey of Commitment to Ultra-Rare Disease Patients: A Supportive Business Model

Over the last 5 years, more than 4000 FDA-regulated clinical trials were initiated worldwide for rare disease treatments. Read more.

2. Drug Combination Leads to 4-Year Survival in Patients with Lung Cancer

A regimen of afatinib as a first-line treatment followed by osimertinib in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer was found to significantly improve overall survival. Read more.

1. FDA Monitoring Data Accuracy Issues with Gene Therapy Product

Officials with the FDA are assessing data accuracy issues related to Zolgensma, but have no major concerns about the spinal muscular atrophy treatment remaining on the market. Read more.

Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 

Related Articles

Top news of the week from Specialty Pharmacy Times.
This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.
Aspirin therapy found to improve liver function test results and survival after transarterial embolization for hepatocellular carcinoma.
Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Contact Us
Terms & Conditions
MJH Associates >
Pharmacy Times
American Journal of Managed Care
MD Magazine
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2019
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.